Retrospective Cohort Study
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Apr 7, 2021; 27(13): 1311-1320
Published online Apr 7, 2021. doi: 10.3748/wjg.v27.i13.1311
Non-responsive celiac disease in children on a gluten free diet
Gopal Veeraraghavan, Amelie Therrien, Maya Degroote, Allison McKeown, Paul D Mitchell, Jocelyn A Silvester, Daniel A Leffler, Alan M Leichtner, Ciaran P Kelly, Dascha C Weir
Gopal Veeraraghavan, Division of Gastro-enterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA 02115, United States
Gopal Veeraraghavan, Amelie Therrien, Jocelyn A Silvester, Daniel A Leffler, Ciaran P Kelly, The Celiac Center, Department of Medicine and Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, MA 02215, United States
Gopal Veeraraghavan, Amelie Therrien, Jocelyn A Silvester, Daniel A Leffler, Alan M Leichtner, Ciaran P Kelly, Dascha C Weir, Celiac Research Program, Harvard Medical School, Boston, MA 02115, United States
Amelie Therrien, Maya Degroote, Allison McKeown, Jocelyn A Silvester, Alan M Leichtner, Dascha C Weir, Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA 02115, United States
Paul D Mitchell, Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, MA 02115, United States
Daniel A Leffler, Gastrointestinal Therapeutics, Takeda Pharmaceutical International Co, Cambridge, MA 02139, United States
Author contributions: Veeraraghavan G, McKeown A, Degroote M, Silvester JA, Leffler DA, Leichtner AM, Kelly CP and Weir DC contributed planning and/or conducting the study; Veeraraghavan G, Therrien A, Degroote M, McKeown A, Mitchell PD, Silvester JA and Weir DC contributed collecting and/or interpreting data; Veeraraghavan G, Therrien A, Degroote M, Mitchell PD, Silvester JA, Leffler DA, Leichtner AM, Kelly CP and Weir DC contributed drafting the manuscript.
Supported by Boston Children's Hospital and the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, No. P30DK034854, No. K23DK119584 and No. T32DK07760; DG Kinnear Award from the Association Quebecoise des Gastroenterologues du Quebec; and Phase 2 Award from the Fonds de Recherche Sante Quebec.
Institutional review board statement: This study was reviewed and approved by the Institutional Review Board of Boston Children’s Hospital.
Informed consent statement: Patients were not required to give informed consent to the study because this study presented no more than minimal risk to patient privacy and confidentiality.
Conflict-of-interest statement: Leffler DA is employed by Takeda Pharmaceuticals International Co. Kelly CP has acted as a scientific advisor to companies attempting to develop new diagnostic and management approaches for Celiac disease including Cour Pharma, Glutenostics, Innovate, Immunogenx and Takeda. He also acts as Principal Investigator on a research grant on Celiac disease supported by Aptalis. Silvester JA has served on an advisory board for Takeda Pharmaceuticals and has received research funding from Biomedal S.L., Cour Pharma and Glutenostics.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dascha C Weir, MD, Attending Physician, Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, 300 Longwood Ave, Boston, MA 02115, United States. dascha.weir@childrens.harvard.edu
Received: December 3, 2020
Peer-review started: December 3, 2020
First decision: December 21, 2020
Revised: January 4, 2021
Accepted: February 1, 2021
Article in press: February 1, 2021
Published online: April 7, 2021
Core Tip

Core Tip: This is a retrospective chart review study of children < 18 years of age diagnosed with celiac disease (CeD) by positive serology and biopsies showing Marsh III histology to characterize non-responsive CeD (NRCD). NRCD was attributed to a wide variety of diagnoses with gluten exposure (30%) and constipation (20%) being the most common causes. Most (64%) patients improved on follow-up. Our study highlights the importance of performing a diligent search for etiologies of NRCD when there are persistent symptoms despite following a gluten-free diet and reinforces the need for close follow up in the first year of the diagnosis of CeD.